Clinical Trial

A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)

Study acronym: NICHOL
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer. Target population will be patients (woman, age \> 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-10.
Status change: Not Yet Recruiting → Recruiting 2025-03-25
Trial Details
NCT Number NCT06594679
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators: GlaxoSmithKline, Eli Lilly and Company
Conditions Ovarian Cancer
Enrollment 73 participants
Start Date 2024-09-26
Primary Completion 2027-03-20 (estimated)
Study Completion 2027-09-18 (estimated)
Updated on ClinicalTrials.gov 2025-03-28